| pubmed-article:3042468 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3042468 | lifeskim:mentions | umls-concept:C0025914 | lld:lifeskim |
| pubmed-article:3042468 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:3042468 | lifeskim:mentions | umls-concept:C0030281 | lld:lifeskim |
| pubmed-article:3042468 | lifeskim:mentions | umls-concept:C0034826 | lld:lifeskim |
| pubmed-article:3042468 | lifeskim:mentions | umls-concept:C0449560 | lld:lifeskim |
| pubmed-article:3042468 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3042468 | pubmed:dateCreated | 1988-9-20 | lld:pubmed |
| pubmed-article:3042468 | pubmed:abstractText | Isolated mouse islets were used to identify the muscarinic receptor subtype present in pancreatic B-cells. We thus compared the inhibitory potencies of atropine (non-specific), of pirenzepine (specific for M1 receptors) and of compound AF-DX 116 (specific for cardiac M2 receptors) on acetylcholine-induced insulin release, 86Rb+ efflux and 45Ca2+ efflux. The three antagonists inhibited all effects of acetylcholine, but EC50 values were markedly different: atropine = 1.5-5 nM, pirenzepine = 0.6-1.7 microM and AF-DX 116 = 1.7-11 microM. The results did not suggest that the various effects of ACh could result from the activation of different subtypes of receptors. It is concluded that muscarinic receptors of pancreatic B-cells belong to an M2 subtype distinct from the cardiac M2 receptors. | lld:pubmed |
| pubmed-article:3042468 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3042468 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3042468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042468 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3042468 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:3042468 | pubmed:issn | 0014-5793 | lld:pubmed |
| pubmed-article:3042468 | pubmed:author | pubmed-author:HenquinJ CJC | lld:pubmed |
| pubmed-article:3042468 | pubmed:author | pubmed-author:NenquinMM | lld:pubmed |
| pubmed-article:3042468 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3042468 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:3042468 | pubmed:volume | 236 | lld:pubmed |
| pubmed-article:3042468 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3042468 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3042468 | pubmed:pagination | 89-92 | lld:pubmed |
| pubmed-article:3042468 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:meshHeading | pubmed-meshheading:3042468-... | lld:pubmed |
| pubmed-article:3042468 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3042468 | pubmed:articleTitle | The muscarinic receptor subtype in mouse pancreatic B-cells. | lld:pubmed |
| pubmed-article:3042468 | pubmed:affiliation | Unité de Diabétologie et Nutrition, University of Louvain, Faculty of Medicine, Brussels, Belgium. | lld:pubmed |
| pubmed-article:3042468 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3042468 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:3042468 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042468 | lld:pubmed |
